Novel benzene sulfonamides with acetylcholinesterase and carbonic anhydrase inhibitory actions

A series of benzene sulfonamides 15-26 were synthesized and determined for their in vitro and in silico inhibitory profiles toward acetylcholinesterase (AChE) and carbonic anhydrases (CAs). Commercially available 3,4-dimethoxytoluene was reacted with chlorosulfonic acid to furnish benzene sulfonyl chloride derivatives. The reaction of substituted benzene sulfonyl chloride with some amines also including (+/-)-alpha-amino acid methyl esters afforded a series of novel benzene sulfonamides. In this study, the enzyme inhibition abilities of these compounds were evaluated against AChE and CAs. They exhibited a highly potent inhibition ability on AChE and -CAs (Ki values are in the range of 28.11 +/- 4.55 nM and 145.52 +/- 28.68 nM for AChE, 39.20 +/- 2.10 nM to 131.54 +/- 12.82 nM for CA I, and 50.96 +/- 9.83 nM and 147.94 +/- 18.75 nM for CA II). The present newly synthesized novel benzene sulfonamides displayed efficient inhibitory profiles against AChE and CAs, and it is anticipated that they may emerge as lead molecules for some diseases including glaucoma, epilepsy, and Alzheimer's disease. A series of benzene sulfonamides were synthesized and determined for their in vitro and in silico inhibitory profiles toward acetylcholinesterase (AChE) and carbonic anhydrase enzymes (CAs). The synthesized compounds exhibited a highly potent inhibition ability on AChE and CAs and may serve as lead molecules for some diseases including glaucoma, epilepsy, and Alzheimer's disease. image